These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15116297)

  • 1. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
    Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
    J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D.
    Iwasenko JM; Scott GM; Rawlinson WD; Keogh A; Mitchell D; Chou S
    J Med Virol; 2009 Mar; 81(3):507-10. PubMed ID: 19152402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.
    Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S
    Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection.
    Rose J; Emery VC; Kumar D; Asberg A; Hartmann A; Jardine AG; Bignamini AA; Humar A; Neumann AU
    PLoS Pathog; 2017 Apr; 13(4):e1006299. PubMed ID: 28406982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance of human cytomegalovirus to antiviral drugs.
    Erice A
    Clin Microbiol Rev; 1999 Apr; 12(2):286-97. PubMed ID: 10194460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction.
    Jorgenson MR; Descourouez JL; Saddler CM; Smith JA; Odorico JS; Rice JP; Mandelbrot DA
    Clin Transplant; 2023 Dec; 37(12):e15142. PubMed ID: 37755141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of standardized protocols for cytomegalovirus disease prevention in pediatric solid organ transplant recipients.
    Ganapathi L; Blumenthal J; Alawdah L; Lewis L; Gilarde J; Jones S; Milliren C; Kim HB; Sharma TS
    Pediatr Transplant; 2019 Nov; 23(7):e13568. PubMed ID: 31515909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
    Caldés A; Colom H; Armendariz Y; Garrido MJ; Troconiz IF; Gil-Vernet S; Lloberas N; Pou L; Peraire C; Grinyó JM
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4816-24. PubMed ID: 19738014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The devil is in the details: Nuances of pre-emptive therapy for cytomegalovirus disease prevention in high-risk seropositive donors liver transplant recipients.
    Heldman MR; Limaye AP
    Transpl Infect Dis; 2024 Jun; 26(3):e14234. PubMed ID: 38191775
    [No Abstract]   [Full Text] [Related]  

  • 10. Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation.
    Chou S; Watanabe J
    Antiviral Res; 2024 Aug; 228():105935. PubMed ID: 38880196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges for the improvement of valganciclovir prophylaxis in solid organ transplantation and the possible role of therapeutic drug monitoring in adults.
    van Vugt LK; Hesselink DA; de Winter BCM
    Br J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38889884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valganciclovir and Risk for Neutropenia: When the Friend Becomes the Foe.
    Nalli N; Teoh CW; Allen U
    Pediatr Transplant; 2024 Aug; 28(5):e14817. PubMed ID: 39030959
    [No Abstract]   [Full Text] [Related]  

  • 13. Comment on "Evaluation of valganciclovir's neutropenia risk in pediatric solid organ transplant recipients utilizing two dosing regimens".
    Daungsupawong H; Wiwanitkit V
    Pediatr Transplant; 2024 May; 28(3):e14754. PubMed ID: 38623879
    [No Abstract]   [Full Text] [Related]  

  • 14. Correction to: Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.
    Clin Infect Dis; 2024 Aug; ():. PubMed ID: 39095060
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
    Vernooij RW; Michael M; Ladhani M; Webster AC; Strippoli GF; Craig JC; Hodson EM
    Cochrane Database Syst Rev; 2024 May; 5(5):CD003774. PubMed ID: 38700045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Treatment Options for Refractory/Resistant CMV Infection.
    Walti CS; Khanna N; Avery RK; Helanterä I
    Transpl Int; 2023; 36():11785. PubMed ID: 37901297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis.
    Wong DD; van Zuylen WJ; Novos T; Stocker S; Reuter SE; Au J; Foster CSP; Day RO; Horvath AR; Endre Z; Rawlinson WD
    Microbiol Spectr; 2022 Jun; 10(3):e0268421. PubMed ID: 35658598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus Infection and the Implications of Drug-Resistant Mutations in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Retrospective Study from a Tertiary Hospital in China.
    Yu U; Wang X; Zhang X; Wang C; Yang C; Zhou X; Li Y; Huang X; Wen J; Wen F; Liu S
    Infect Dis Ther; 2021 Sep; 10(3):1309-1322. PubMed ID: 33966176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper
    Abdul-Aziz MH; Alffenaar JC; Bassetti M; Bracht H; Dimopoulos G; Marriott D; Neely MN; Paiva JA; Pea F; Sjovall F; Timsit JF; Udy AA; Wicha SG; Zeitlinger M; De Waele JJ; Roberts JA; ; ; ;
    Intensive Care Med; 2020 Jun; 46(6):1127-1153. PubMed ID: 32383061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands.
    Van Leer Buter CC; de Voogd DWK; Blokzijl H; de Joode AAE; Berger SP; Verschuuren EAM; Niesters HGM
    J Antimicrob Chemother; 2019 Aug; 74(8):2370-2376. PubMed ID: 31093660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.